Does the media favor APGE or MRNA?

In the previous week, Moderna had 16 more articles in the media than Apogee Therapeutics. MarketBeat recorded 24 mentions for Moderna and 8 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat Moderna's score of 0.49 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media favor VTRS or APGE?

In the previous week, Apogee Therapeutics had 4 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Apogee Therapeutics and 4 mentions for Viatris. Viatris' average media sentiment score of 0.77 beat Apogee Therapeutics' score of 0.68 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer APGE or GMAB?

In the previous week, Apogee Therapeutics had 6 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Apogee Therapeutics and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Apogee Therapeutics' score of 0.68 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to APGE or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 8 mentions for Apogee Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Apogee Therapeutics' score of 0.68 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or APGE?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 8 mentions for Apogee Therapeutics. BridgeBio Pharma's average media sentiment score of 0.75 beat Apogee Therapeutics' score of 0.68 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Apogee Therapeutics (APGE) Competitors

$82.72 -2.28 (-2.68%)

Closing price 04:00 PM Eastern

Extended Trading

$82.71 -0.01 (-0.01%)

As of 04:12 PM Eastern

Compare

APGE vs. MRNA, VTRS, GMAB, ASND, and BBIO

Should you buy Apogee Therapeutics stock or one of its competitors? MarketBeat compares Apogee Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apogee Therapeutics include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

How does Apogee Therapeutics compare to Moderna?

Apogee Therapeutics (NASDAQ:APGE) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Apogee Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Moderna	-143.55%	-26.64%	-19.32%

Apogee Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Apogee Therapeutics has higher earnings, but lower revenue than Moderna. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Moderna	$1.94B	9.39	-$2.82B	-$8.15	N/A

Apogee Therapeutics presently has a consensus target price of $114.56, suggesting a potential upside of 38.49%. Moderna has a consensus target price of $36.60, suggesting a potential downside of 20.42%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Apogee Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Moderna had 16 more articles in the media than Apogee Therapeutics. MarketBeat recorded 24 mentions for Moderna and 8 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat Moderna's score of 0.49 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Apogee Therapeutics beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 4 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Apogee Therapeutics and 4 mentions for Viatris. Viatris' average media sentiment score of 0.77 beat Apogee Therapeutics' score of 0.68 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Viatris presently has a consensus price target of $17.50, suggesting a potential upside of 10.97%. Apogee Therapeutics has a consensus price target of $114.56, suggesting a potential upside of 38.49%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

Apogee Therapeutics beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Genmab A/S?

Apogee Therapeutics (NASDAQ:APGE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Apogee Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Genmab A/S	$3.72B	4.10	$963M	$1.32	18.55

In the previous week, Apogee Therapeutics had 6 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Apogee Therapeutics and 2 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Apogee Therapeutics' score of 0.68 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics currently has a consensus target price of $114.56, indicating a potential upside of 38.49%. Genmab A/S has a consensus target price of $37.93, indicating a potential upside of 54.87%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 21.05% compared to Apogee Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Apogee Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Ascendis Pharma A/S?

Apogee Therapeutics (NASDAQ:APGE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Apogee Therapeutics currently has a consensus price target of $114.56, suggesting a potential upside of 38.49%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 40.80%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 8 mentions for Apogee Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Apogee Therapeutics' score of 0.68 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Apogee Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Apogee Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Ascendis Pharma A/S	$814.57M	16.07	-$258M	$8.67	24.20

Summary

Ascendis Pharma A/S beats Apogee Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Apogee Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.30	-$724.93M	-$3.74	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

BridgeBio Pharma currently has a consensus target price of $89.59, indicating a potential upside of 32.90%. Apogee Therapeutics has a consensus target price of $114.56, indicating a potential upside of 38.49%. Given Apogee Therapeutics' higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

In the previous week, BridgeBio Pharma had 6 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for BridgeBio Pharma and 8 mentions for Apogee Therapeutics. BridgeBio Pharma's average media sentiment score of 0.75 beat Apogee Therapeutics' score of 0.68 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apogee Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Summary

BridgeBio Pharma beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.12B	$3.29B	$6.43B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-19.10	18.99	24.48	23.65
Price / Sales	N/A	291.27	501.18	105.07
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	6.25	8.01	10.43	6.73
Net Income	-$255.84M	$23.89M	$3.56B	$337.26M
7 Day Performance	-1.75%	-3.35%	-1.30%	-1.25%
1 Month Performance	-0.37%	1.30%	0.99%	1.33%
1 Year Performance	96.86%	34.58%	19.51%	22.79%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	3.2115 of 5 stars	$82.72 -2.7%	$114.56 +38.5%	+111.8%	$5.12B	N/A	N/A	91	Analyst Forecast
MRNA Moderna	1.3258 of 5 stars	$47.23 -0.8%	$36.60 -22.5%	+69.6%	$18.75B	$1.94B	N/A	4,700	Analyst Forecast Insider Trade
VTRS Viatris	3.1636 of 5 stars	$16.10 +1.1%	$17.50 +8.7%	+83.9%	$18.72B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.4753 of 5 stars	$25.06 +1.0%	$37.93 +51.4%	+12.8%	$15.62B	$3.72B	18.98	3,029	Gap Down
ASND Ascendis Pharma A/S	4.6953 of 5 stars	$212.71 +3.4%	$295.39 +38.9%	+23.1%	$13.30B	$814.57M	24.58	1,189	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. MRNA, VTRS, GMAB, ASND, and BBIO

How does Apogee Therapeutics compare to Moderna?

Summary

How does Apogee Therapeutics compare to Viatris?

Summary

How does Apogee Therapeutics compare to Genmab A/S?

Summary

How does Apogee Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Apogee Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. MRNA, VTRS, GMAB, ASND, and BBIO

How does Apogee Therapeutics compare to Moderna?

Is APGE or MRNA more profitable?

Which has more volatility and risk, APGE or MRNA?

Which has better valuation and earnings, APGE or MRNA?

Do analysts prefer APGE or MRNA?

Does the media favor APGE or MRNA?

Do insiders and institutionals hold more shares of APGE or MRNA?

Summary

How does Apogee Therapeutics compare to Viatris?

Do institutionals & insiders hold more shares of VTRS or APGE?

Which has better earnings and valuation, VTRS or APGE?

Does the media favor VTRS or APGE?

Is VTRS or APGE more profitable?

Do analysts rate VTRS or APGE?

Which has more risk and volatility, VTRS or APGE?

Summary

How does Apogee Therapeutics compare to Genmab A/S?

Which has more volatility and risk, APGE or GMAB?

Which has stronger earnings & valuation, APGE or GMAB?

Does the media prefer APGE or GMAB?

Do analysts recommend APGE or GMAB?

Do institutionals and insiders believe in APGE or GMAB?

Is APGE or GMAB more profitable?

Summary

How does Apogee Therapeutics compare to Ascendis Pharma A/S?

Do insiders and institutionals believe in APGE or ASND?

Which has more volatility and risk, APGE or ASND?

Do analysts prefer APGE or ASND?

Does the media refer more to APGE or ASND?

Is APGE or ASND more profitable?

Which has stronger valuation and earnings, APGE or ASND?

Summary

How does Apogee Therapeutics compare to BridgeBio Pharma?

Which has higher earnings and valuation, BBIO or APGE?

Do analysts recommend BBIO or APGE?

Does the media prefer BBIO or APGE?

Which has more risk and volatility, BBIO or APGE?

Do insiders & institutionals believe in BBIO or APGE?

Is BBIO or APGE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools